查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947982

发炎性肠道疾病小分子药物市场：依适应症、作用机制、通路、治疗类型、治疗线和研发阶段划分，全球预测（2026-2032年）

Small Molecules Drugs for Inflammatory Bowel Diseases Market by Indication, Mechanism Of Action, Distribution Channel, Treatment Type, Therapy Line, Development Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，用于治疗发炎性肠道疾病的小分子药物市场价值将达到 22.7 亿美元，到 2026 年将成长至 23.6 亿美元，到 2032 年将达到 33.8 亿美元，复合年增长率为 5.85%。

关键市场统计数据
基准年 2025 22.7亿美元
预计年份：2026年 23.6亿美元
预测年份 2032 33.8亿美元
复合年增长率 (%) 5.85%

深入探讨口服小分子疗法如何重塑发炎性肠道疾病的治疗路径和相关人员策略

随着小分子药物与生物製药的互补作用以及治疗路径的重塑，发炎性肠道疾病（IBD）的治疗模式正在发生显着变化。我们对免疫讯号传导、肠道屏障生物学以及靶向细胞内通路认识的不断深入，推动了口服疗法的重要性日益凸显。口服疗法具有给药方便、药物动力学可预测以及潜在的差异化安全性等优势。随着患者对更易于管理的给药方案和更轻鬆的用药负担的日益增长，相关人员正在重新评估其临床策略，以便将这些治疗方法纳入诱导治疗和维持治疗中。

基于机制的精准治疗、适应性临床设计和新型商业化模式如何共同改变小分子发炎性肠道疾病治疗药物的研发和获取格局

近年来，药物研发和商业化模式已发生系统性转变，不再局限于单一分子。细胞内讯号传递精准标靶化已从概念走向临床应用，催生出选择性和频谱抑制剂，这些抑制剂可根据特定患者表型和先前治疗史进行客製化。这种机制上的精细化正在推动更具适应性的临床项目，并加速进行旨在证明以患者为中心的临床疗效指标优于其他疗法的比较疗效研究。

评估2025年关税变化将如何影响小分子IBD治疗药物的研发和商业化过程中的供应链韧性、筹资策略以及成本控制需求。

贸易和关税框架的政策调整可能会对整个医药供应链产生连锁反应，影响成本、筹资策略和风险缓解措施，但不会直接改变临床决策。提高进口活性药物原料药和辅料的关税可能会促使采购行为转向多元化的供应商网络，或鼓励本地或区域性生产投资。采购团队可能会透过提高供应商资格标准、协商长期合约或加快双重采购策略来应对，以维持供应的连续性并降低投入成本的波动性。

深度细分洞察揭示了适应症严重程度、作用机制差异、分销管道、治疗方案和研发阶段如何影响策略性临床和商业性决策。

跨适应症细分揭示了对克隆氏症和溃疡性大肠炎的双重关注，并根据疾病的轻度、中度和重度状态，对每种适应症进行区分，从而决定临床实验入组、临床终点和治疗定位。针对中重度患者族群的产品通常优先考虑持久缓解和减少荷尔蒙用量的疗效，而针对轻度疾病的治疗方法则强调耐受性和长期维持耐受性。这种基于适应症的详细细分为研发策略和商业性准入策略提供了依据，并指导临床专案设计和支付方价值提案。

比较美洲、欧洲、中东、非洲和亚太地区的区域趋势和存取需求，这些趋势和需求将影响监管策略和商业性实施。

区域趋势凸显了美洲、欧洲、中东和非洲以及亚太地区在优先事项上的差异，这些差异影响着监管互动、市场进入途径和商业性执行模式。在美洲，集中化的监管途径和口服小分子药物的经验促进了某些医疗机构的快速临床应用，而支付方分散和报销政策的多样性则要求制定量身定制的证据材料和差异化的定价策略。美国通常为商业性和市场准入预期树立先例，而更广泛的泛美市场则展现了多样化上市顺序和本地伙伴关係模式的潜力。

深入了解成熟的製药巨头、灵活的生物技术公司和服务合作伙伴如何塑造发炎性肠道疾病 (IBD) 领域的研发管线成熟度、合作关係和商业性差异化策略。

小分子发炎性肠道疾病（IBD）领域的企业策略呈现出多元化的特点，包括资金雄厚的成熟製药公司、灵活的专业生物技术公司以及以服务为导向的合作伙伴，它们共同塑造着创新、规模化生产和市场准入。大型製药企业倾向于利用其成熟的监管经验、全球商业基础设施和广泛的药物监测能力，指导后期研发专案获得核准并实现广泛分销。这些公司通常优先考虑生命週期管理和适应症拓展，以巩固其长期市场地位并应对来自生物相似药和学名药的竞争。

为建立可持续的竞争优势，提出将基于机制的研发、稳健的供应策略和以支付方为中心的证据生成相结合的实用建议

为了充分发挥临床和商业性价值，产业领导者应优先采取三项行动：投资于基于机制的差异化研发、增强价值链韧性以及製定符合支付方预期的循证策略。首先，将研发资源集中在明确的机制优势（即能够转化为实际临床获益的优势）将有助于药物在竞争激烈的市场环境中脱颖而出。应围绕明确的终点指标开发选择性、安全性权衡以及新型受体调节机制，这些指标应能引起临床医师和支付者的重视。此外，这些项目还应纳入生物标记和患者报告结局，以进一步强化差异化优势。

我们采用透明的多方法研究途径，结合监管审查、临床数据分析、相关人员访谈和细分框架来检验策略见解。

本分析采用多方面的研究方法，结合全面的文献综述、监管申报资料审查、临床试验註册资料以及与关键相关人员的访谈，以验证研究结果并检验策略性结论。科学文献和同行评审的临床数据为作用机制和安全性分析奠定了基础，而监管申报资料和产品标籤则提供了比较优势和核准适应症的资讯。临床试验註册资料用于追踪研发进展，并绘製不同阶段和终点的设计趋势图。

科学差异化、业务永续营运和实证准入策略之间相互作用的综述，这些因素将决定小分子IBD疗法的长期成功。

总之，发炎性肠道疾病小分子药物领域正发展成为一个更为复杂的生态系统，机制的精准性、分销策略和可靠的实证医学证据将共同决定其长期疗效。口服调节剂如今已成为从诱导治疗到维持治疗的重要选择，其应用取决于疗效、安全性和患者便利性方面的显着差异。临床试验设计、支付方预期和真实世界疗效之间的相互作用，将日益决定哪些产品能够在各个治疗领域中持续成功。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 发炎性肠道疾病小分子药物市场（依适应症划分）

  • 克隆氏症
    • 温和的
    • 缓和
    • 严重
  • 溃疡性大肠炎
    • 温和的
    • 缓和
    • 严重

9. 依作用机转分類的发炎性肠道疾病小分子药物市场

  • JAK抑制剂
    • JAK1选择性抑制剂
    • 泛JAK抑制剂
  • PDE4抑制剂
  • S1P受体调变器
    • S1P1调变器
    • S1P1/5调变器

10. 发炎性肠道疾病小分子药物市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

11. 依治疗类型分類的发炎性肠道疾病小分子药物市场

  • 诱导治疗
  • 维持治疗

12. 发炎性肠道疾病小分子药物市场（依治疗类别划分）

  • 一线治疗
  • 二线治疗
  • 三线治疗及后续治疗

13. 依研发阶段分類的发炎性肠道疾病小分子药物市场

  • 已通过核准的
  • 临床二期
  • 临床III期

14. 各地区发炎性肠道疾病小分子药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 发炎性肠道疾病小分子药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国发炎性肠道疾病小分子药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国小分子药物市场（用于治疗发炎性肠道疾病）

18. 中国：发炎性肠道疾病小分子药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-4F7A6D4FB6C1

The Small Molecules Drugs for Inflammatory Bowel Diseases Market was valued at USD 2.27 billion in 2025 and is projected to grow to USD 2.36 billion in 2026, with a CAGR of 5.85%, reaching USD 3.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.27 billion
Estimated Year [2026] USD 2.36 billion
Forecast Year [2032] USD 3.38 billion
CAGR (%) 5.85%

An in-depth introduction to how oral small molecule therapeutics are reshaping treatment pathways and stakeholder strategies across inflammatory bowel disease care

The therapeutic landscape for inflammatory bowel diseases is undergoing a marked transformation as small molecule agents increasingly complement biologic options and redefine treatment pathways. Advances in understanding of immune signaling, intestinal barrier biology, and targeted intracellular pathways have elevated the relevance of oral therapies that offer convenience, predictable pharmacokinetics, and the potential for differentiated safety profiles. Against a backdrop of rising patient expectations for manageable dosing regimens and reduced administration burden, stakeholders are reassessing clinical strategies to incorporate these therapies across both induction and maintenance settings.

Clinicians and payers are adapting to a more complex armamentarium that includes selective kinase inhibitors, intracellular signaling modulators, and sphingosine 1-phosphate receptor modulators. This proliferation of mechanism diversity has reshaped trial design, endpoint selection, and real-world evidence generation. As a result, development programs are optimizing patient selection, stratifying by disease severity and prior therapy exposure, and emphasizing end points that matter to patients, such as sustained steroid-free remission and mucosal healing.

Industry leaders are responding by refining go-to-market models, aligning manufacturing and supply chains with oral formulation demands, and investing in post-approval evidence generation to support long-term safety narratives. Policy shifts, payer negotiations, and evolving clinical guidelines are converging to create both opportunities and constraints for small molecules; therefore, a granular understanding of clinical differentiation, regulatory positioning, and commercialization nuance is essential for informed decision-making.

How mechanistic precision, adaptive clinical design, and novel commercialization models are collectively transforming development and access dynamics in small molecule IBD care

Recent years have seen transformative shifts that extend beyond individual molecules to systemic changes in development and commercialization paradigms. Precision targeting within intracellular signaling cascades has matured from concept to clinic, enabling the emergence of both selective and broad-spectrum inhibitors that can be matched to distinct patient phenotypes and prior treatment exposures. This mechanistic refinement has driven more adaptive clinical programs and accelerated comparative effectiveness efforts aimed at demonstrating clinical advantage in meaningful patient-centric outcomes.

Parallel to scientific advances, regulatory and clinical practice patterns are evolving to accommodate novel trial architectures, including head-to-head and pragmatic studies that reflect routine care. The increasing emphasis on safety surveillance and long-term outcome data has encouraged sponsors to integrate real-world data streams and registries early in development. Commercially, digital engagement models and specialty pharmacy partnerships are redefining patient support and adherence management for oral therapies, while payers demand robust evidence packages that illustrate value over existing standards of care.

These shifts are compounded by competitive dynamics among diverse players ranging from established pharmaceutical companies to nimble biotechs that specialize in kinase chemistry or receptor modulation. Collaboration, licensing, and strategic alliances have become integral to building comprehensive pipelines that span induction to maintenance therapy and first-line to refractory settings. Together, these scientific, regulatory, and commercial inflections are converging to accelerate adoption cycles for differentiated small molecule therapies, while also elevating the bar for evidence, access, and long-term risk management.

Assessing how tariff changes in 2025 can reshape supply chain resilience, sourcing strategies, and cost-containment imperatives across small molecule IBD development and commercialization

Policy adjustments in trade and tariff frameworks can ripple across pharmaceutical supply chains in ways that influence costs, sourcing strategies, and risk mitigation choices without directly altering clinical decision-making. Increased tariffs on imported active pharmaceutical ingredients or excipients can shift procurement behavior toward diversified supplier networks or incentivize local or regional manufacturing investments. Procurement teams may respond by broadening qualification criteria for suppliers, negotiating longer-term contracts, or accelerating dual-sourcing strategies to preserve continuity of supply and contain input volatility.

The cumulative effect of tariff changes in 2025 can also prompt manufacturers to reassess cost structures and take proactive measures that include reconfiguring production footprints, adopting vertical integration for critical components, or adjusting pricing strategies within allowable regulatory and reimbursement frameworks. Where tariffs materially affect input costs, companies typically seek efficiency improvements in formulation and manufacturing, and may accelerate portfolio rationalization or strategic prioritization to sustain margins without compromising clinical development investments.

From a regulatory and market access standpoint, tariffs can indirectly affect timelines through supply constraints or reallocations of commercial inventories, which in turn shape launch sequencing and stakeholder negotiations. Payers and health systems facing broader inflationary pressures may increase scrutiny on cost-effectiveness and demand clearer evidence of comparative value for new oral therapeutics. Consequently, organizational priorities often shift toward resilient sourcing, scenario planning for supply disruptions, and targeted evidence generation that supports reimbursement conversations in a more cost-sensitive environment.

Deep segmentation insights showing how indication severity, mechanism differentiation, distribution choices, therapy line, and development stage drive strategic clinical and commercial decisions

Segmentation across indication highlights the dual focus on Crohn disease and ulcerative colitis, and within each indication differentiation by mild, moderate, and severe disease states governs trial enrollment, clinical end points, and therapeutic positioning. Products aimed at moderate-to-severe populations typically prioritize durable remission and steroid-sparing outcomes, whereas therapies targeting mild disease emphasize tolerability and long-term maintenance tolerability. This granular indication-based segmentation informs both development strategies and commercial access approaches, guiding clinical program design and payer value narratives.

Mechanism of action segmentation clarifies how JAK inhibitors, PDE4 inhibitors, and S1P receptor modulators occupy distinct therapeutic niches. Within the class of JAK inhibitors, delineation between JAK1 selective compounds and pan-JAK inhibitors creates opportunities to position agents based on safety and efficacy trade-offs, while S1P receptor modulators subdivide into S1P1 focused molecules and S1P1/5 agents that may differ in pharmacology and adverse event profiles. PDE4 inhibitors offer another intracellular signaling approach with potential advantages in oral tolerability and immunomodulation, and these mechanistic categories drive differentiated clinical development plans and post-marketing surveillance needs.

Distribution channel segmentation shapes patient access and adherence strategies because hospital pharmacy, online pharmacy, and retail pharmacy pathways each impose different logistical, regulatory, and payer considerations. Hospital pharmacies may support inpatient or infusion-adjacent workflows and facilitate stewardship and monitoring, whereas online and retail pharmacies enable broad outpatient distribution and patient convenience. Treatment type segmentation between induction therapy and maintenance therapy influences trial timing, outcome measures, and lifecycle management decisions, as induction benefits must translate into sustained maintenance outcomes to support long-term adoption.

Therapy line segmentation-first line, second line, and third line and beyond-determines comparator selection, patient populations, and value proposition messaging, as therapies moving into earlier lines must demonstrate either superior efficacy, improved safety, or clear convenience advantages. Development stage segmentation into approved, clinical Phase II, and clinical Phase III cohorts signals where clinical risk and evidence uncertainty lie, guiding partnership, licensing, and investment decisions. Together, these segmentation lenses provide a multi-dimensional framework for aligning clinical development with commercial strategy, regulatory planning, and real-world evidence generation.

Comparative regional dynamics and access imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy and commercial execution

Regional dynamics underscore differentiated priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific and influence regulatory interactions, market access pathways, and commercial execution models. In the Americas, centralized regulatory pathways and experience with oral small molecules have fostered rapid clinical adoption in certain care settings, but payer fragmentation and varied reimbursement policies require tailored evidence packages and differentiated pricing strategies. The United States often sets precedence for commercial and access expectations, while broader Pan-American markets may present opportunities for varied launch sequencing and local partnership models.

Europe Middle East & Africa presents a mosaic of regulatory frameworks and procurement mechanisms that favor consolidated health technology assessment submissions and negotiated pricing agreements. Regional variation in formularies and reimbursement criteria compels sponsors to invest in robust health economics and outcomes research to satisfy diverse national decision-making bodies. In many EMEA markets, early demonstration of cost-effectiveness and real-world comparative effectiveness can significantly influence uptake trajectories and placement on national formularies.

Asia-Pacific is shaped by rapid adoption in some jurisdictions, growing domestic manufacturing capabilities, and heterogeneous regulatory environments that range from highly centralized approvals to country-specific dossier requirements. Payers across the region are increasingly focused on affordability and local evidence generation, prompting sponsors to consider innovative pricing models, risk-sharing agreements, and locally relevant clinical research. Across all regions, localized patient support programs, culturally appropriate engagement strategies, and partnership ecosystems are critical to achieving sustainable access and adherence for oral small molecule therapies.

Insight into how established pharmaceutical leaders, nimble biotechs, and service partners are shaping pipeline maturation, alliances, and commercial differentiation strategies in IBD

Company strategies in the small molecule IBD space are characterized by a mix of deep-pocketed pharmaceutical incumbents, nimble specialty biotechs, and service-oriented partners that together shape innovation, scale-up, and market entry. Larger pharmaceutical organizations tend to leverage established regulatory experience, global commercial infrastructure, and expansive pharmacovigilance capabilities to shepherd late-stage assets through approval and into broad distribution. These firms often prioritize lifecycle management and label expansion to solidify long-term positioning and to defend against biosimilar and generic competition.

Specialty biotech companies frequently lead early-stage innovation with focused chemistry and biology expertise, advancing differentiated mechanisms or selective kinase profiles that address unmet aspects of disease control. Such companies regularly seek strategic collaborations or licensing arrangements with larger partners to access late-stage development resources and commercial reach. Contract development and manufacturing organizations play an essential role in enabling scale-up of oral formulations, flexible production scheduling, and qualification of multiple supply sources to minimize disruption risks.

Across the ecosystem, strategic partnerships, out-licensing deals, and targeted M&A activity remain common levers for accelerating portfolios and filling therapeutic gaps. Companies are also investing in real-world evidence platforms and digital health solutions to support adherence, monitor safety signals, and generate long-term outcome data required by payers and regulatory bodies. The competitive landscape rewards organizations that can integrate clinical differentiation with pragmatic access strategies and the operational capacity to scale globally while adapting to regional nuances.

Action-oriented recommendations for leaders to align mechanistic R&D, resilient supply strategies, and payer-focused evidence generation for sustainable competitive advantage

Industry leaders should prioritize a triad of actions to capture clinical and commercial value: invest in mechanism-driven differentiation, strengthen supply chain resilience, and design evidence strategies aligned with payer expectations. First, focusing R&D resources on clear mechanistic advantages that translate into tangible clinical benefits will help delineate agents in a crowded landscape. Selectivity profiles, safety trade-offs, and novel receptor modulation should be developed with clear end points that resonate with clinicians and payers, and those programs should incorporate biomarkers and patient-reported outcomes to enhance differentiation.

Second, supply chain and procurement strategies must assume a higher baseline of geopolitical and trade volatility. Establishing qualified multi-sourcing, regional manufacturing options, and inventory buffers can mitigate the impact of external tariff or trade shifts. Operational investments should include scenario-based planning and collaborative supplier relationships that enable rapid response to input cost fluctuations or logistics disruptions. Third, early and continuous engagement with payers and health technology assessment bodies will streamline access pathways. Evidence generation plans should be pragmatic, incorporating randomized and real-world study formats, and should demonstrate value across induction and maintenance use cases and across therapy line placements.

Additionally, companies should cultivate partnerships that accelerate commercialization, from specialty pharmacy collaborations that support adherence to digital health vendors that enable remote monitoring. Embracing flexible pricing arrangements and risk-sharing models where appropriate can ease payer concerns and facilitate broader adoption. Finally, organizations must invest in cross-functional capabilities that align clinical development with commercial launch readiness, regulatory strategy, and post-market surveillance to ensure sustainable uptake and long-term patient benefit.

A transparent multi-method research approach blending regulatory review, clinical data analysis, stakeholder interviews, and segmentation frameworks to validate strategic insights

This analysis integrates a multi-source research methodology that combines comprehensive literature synthesis, regulatory dossier reviews, clinical trial registries, and primary stakeholder interviews to triangulate findings and validate strategic conclusions. Scientific literature and peer-reviewed clinical data provide the foundation for mechanistic and safety insights, while regulatory filings and product labels inform comparative positioning and approved indications. Clinical trial registries are used to track development stage transitions and to map design trends across phases and endpoints.

Primary research includes structured interviews with clinical investigators, medical affairs professionals, payers, and specialty pharmacists to capture real-world practice patterns, access barriers, and formulary considerations. These qualitative inputs are cross-referenced with secondary sources to ensure consistency and to surface divergent views that require deeper analysis. Supply chain and policy impact assessments utilize trade data, manufacturing disclosures, and expert commentary to evaluate sourcing vulnerabilities and adaptive strategies.

Analytical frameworks applied in the research include segmentation mapping across indication severity, mechanism of action, distribution channels, treatment type, therapy line, and development stage, enabling multi-dimensional synthesis of clinical and commercial implications. Where possible, findings are contextualized by regulatory precedent and published safety profiles, ensuring that recommendations are grounded in current evidence and practical considerations relevant to development and commercialization decisions.

Concluding synthesis on the interplay of scientific differentiation, operational resilience, and evidence-driven access strategies that determine long-term success in small molecule IBD therapies

In summary, the small molecule therapeutic landscape for inflammatory bowel diseases is evolving into a more nuanced ecosystem where mechanistic precision, distribution strategies, and robust evidence generation converge to determine long-term success. Oral modulators now represent critical options across induction and maintenance settings, and their adoption will hinge on clear differentiators in efficacy, safety, and patient convenience. The interplay between clinical trial design, payer expectations, and real-world performance will increasingly define which products achieve durable placement across therapy lines.

Operational resilience in sourcing and manufacturing, together with proactive engagement with payers and regulators, will be key to mitigating policy and tariff-related pressures that can affect supply and access. Strategic alliances and targeted investments in post-approval evidence and digital adherence solutions will further enhance the value proposition for patients and health systems. Ultimately, organizations that integrate deep scientific differentiation with pragmatic commercialization execution and adaptable supply chain strategies will be best positioned to translate therapeutic innovation into sustained patient impact and commercial viability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Indication

  • 8.1. Crohn Disease
    • 8.1.1. Mild
    • 8.1.2. Moderate
    • 8.1.3. Severe
  • 8.2. Ulcerative Colitis
    • 8.2.1. Mild
    • 8.2.2. Moderate
    • 8.2.3. Severe

9. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Mechanism Of Action

  • 9.1. JAK Inhibitors
    • 9.1.1. JAK1 Selective Inhibitors
    • 9.1.2. Pan JAK Inhibitors
  • 9.2. PDE4 Inhibitors
  • 9.3. S1P Receptor Modulators
    • 9.3.1. S1P1 Modulators
    • 9.3.2. S1P1/5 Modulators

10. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Treatment Type

  • 11.1. Induction Therapy
  • 11.2. Maintenance Therapy

12. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Therapy Line

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Line And Beyond

13. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Development Stage

  • 13.1. Approved
  • 13.2. Clinical Phase II
  • 13.3. Clinical Phase III

14. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Small Molecules Drugs for Inflammatory Bowel Diseases Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Small Molecules Drugs for Inflammatory Bowel Diseases Market

18. China Small Molecules Drugs for Inflammatory Bowel Diseases Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Bristol Myers Squibb Company
  • 19.8. Celgene Corporation
  • 19.9. Eli Lilly and Company
  • 19.10. Galapagos NV
  • 19.11. Gilead Sciences, Inc.
  • 19.12. Gilead Sciences, Inc.
  • 19.13. Johnson & Johnson
  • 19.14. Merck & Co., Inc.
  • 19.15. Mylan N.V.
  • 19.16. Novartis AG
  • 19.17. Pfizer Inc.
  • 19.18. Pfizer Inc.
  • 19.19. Roche Holding AG
  • 19.20. Sandoz International GmbH
  • 19.21. Sun Pharmaceutical Industries Ltd.
  • 19.22. Takeda Pharmaceutical Company Limited
  • 19.23. Teva Pharmaceutical Industries Ltd.
  • 19.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK1 SELECTIVE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PAN JAK INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1 MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P1/5 MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDUCTION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY APPROVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CLINICAL PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 198. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 227. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 228. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY CROHN DISEASE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY JAK INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY S1P RECEPTOR MODULATORS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 245. NATO SMALL MOLECULES DRUGS FOR INFLAMMATORY BOWEL DISEASES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032